A promise of artificial intelligence is that it will gain more value from the complex and expensive data generated in drug discovery, by identifying hidden patterns and valuable conclusions that will guide better decisions when designing and selecting high-quality clinical candidates. Professor John Overington at Medicines Discovery Catapult, Tom Whitehead at Intellegens and Matt Segall at Optibrium describe how to achieve this by aligning different factors.